Protective effects and potential mechanism of the SGLT2 inhibitor on islet β cells
10.3760/cma.j.cn311282-20200814-00577
- VernacularTitle:SGLT2抑制剂对胰岛β细胞的保护作用及潜在机制
- Author:
Kangli WANG
;
Tianpei HONG
;
Rui WEI
- From:
Chinese Journal of Endocrinology and Metabolism
2021;37(4):297-300
- CountryChina
- Language:Chinese
-
Abstract:
Islet β cell protection is one of the key strategies for diabetes treatment. The new antidiabetic drug sodium-glucose cotransporter 2(SGLT2)inhibitor decreases blood glucose by inhibiting glucose reabsorption in the renal tubule, independent of insulin. Various clinical studies have shown that SGLT2 inhibitors improve β cell function. Furthermore, animal experiments have indicated that SGLT2 inhibitors increase β cell mass. SGLT2 inhibitors promote islet regeneration through stimulating β cell proliferation, inhibiting β cell apoptosis and dedifferentiation, enhancing transdifferentiation of α cells to β cells, and initiating progenitor-derived β cell neogenisis. Indirect effects of metabolic improvement(i.e.lowering glucose, losing weight, improving lipid metabolism), inhibiting inflammatory reaction, inducing glucagon-like peptide-1 secreted from α cells, and regulating gene changes might be involved in the β cell protection of SGLT2 inhibitors.
